Resources
8 Results (showing 1 - 8)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Mt. Vernon Square Room on Wednesday, March 4, 2020, at 2:45 PM
Posted 7/26/2023 (updated 3/28/2024)
Sonoran Prevention Works (SPW) shared some of its experiences implementing harm reduction in Cochise County, one of the more rural counties in AZ. SPW provides street-based outreach, testing, and peer support; offers training, education, and technical assistance and TA; and engages in local and state advocacy work.
Posted 7/26/2023 (updated 3/28/2024)
This session covered strategies for successfully attracting and finding candidates, including how to create an effective and compelling job ad and website; developing a sourcing plan; leveraging social media; and incorporating diversity, equity, and inclusion in your marketing efforts.
Posted 7/26/2023 (updated 3/28/2024)
Drake Cooper partnered with JBS International, Inc. (JBS) to help grantees increase their capacity and sustainability through campaign marketing materials built to combat community stigma surrounding substance use disorder (SUD) and OUD.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/26/2023 (updated 3/28/2024)
RSV 2023: 9:00 - 10:45 a.m. Welcome and Keynote Address (Day 1)
Posted 6/7/2022 (updated 3/27/2024)
Stigma and bias among community members, health care providers, and even family members toward individuals with substance use disorder negatively affects the care provided to this population. Stigma prevents individuals from seeking treatment and continues to divide them from their families, their communities, and the evidence-based treatments available.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.